Table 1.
The role of glutathione S-transferases (GST) proteins in the chemoresistance of different cancer model systems is summarized below.
| Tumor Model | Anti-Neoplastic Agent | Outcome | Reference |
|---|---|---|---|
| Ovarian cancer | Cisplatin, doxorubicin | Response rate lower in GSTP1-positive patients | [85,86,87] |
| Glioma | Cisplatin, irinotecan | GSTP1 is overexpressed in resistant tumors | [88,89] |
| Gastric cancer | Fluorouracil (5-FU), cisplatin | GSTP1 is overexpressed in resistant tumors | [90] |
| Prostate cancer | Doxorubicin | GSTP1 is overexpressed in resistant tumors | [91] |
| Breast cancer | Adriamycin | GSTP1 is overexpressed in resistant tumors | [92] |
| Breast cancer | Adriamycin | Increased apoptosis and DNA damage upon GSTP1 knockdown | [93] |
| Esophageal squamous cancer cells | Cisplatin | Synergistic effect of GSTP1 knockdown and cisplatin treatment | [94] |
| Lung cancer stem cells | Cisplatin | Synergistic effect of GSTP1 inhibition and cisplatin treatment | [95] |
| Lung cancer | Camptothecin | Increased apoptosis upon GSTP1 knockdown and camptothecin treatment | [96] |
| Lung cancer stem cells | Cisplatin | miRNA-mediated inhibition of GSTP1 reverses cisplatin resistance | [105] |